SPY420.86+5.94 1.43%
DIA338.78+5.82 1.75%
IXIC14,141.48+111.10 0.79%

BRIEF-IDEAYA Announces Dose Expansion In Phase 1/2 Study Of Darovasertib And Crizotinib Combination

05/10/2021 07:14
BRIEF-IDEAYA Announces Dose Expansion In Phase 1/2 Study Of Darovasertib And Crizotinib Combination

- IDEAYA Biosciences Inc IDYA.O:

  • IDEAYA ANNOUNCES DOSE EXPANSION IN PHASE 1/2 STUDY OF DAROVASERTIB AND CRIZOTINIB COMBINATION BASED ON EARLY CLINICAL EFFICACY IN FIRST COMBINATION COHORT

  • IDEAYA BIOSCIENCES - OBSERVED EFFICACY IN FIRST COHORT OF DAROVASERTIB PLUS CRIZOTINIB COMBINATION WITH TUMOR REDUCTION IN 2 OF 2 EVALUABLE MUM PATIENTS

  • IDEAYA BIOSCIENCES INC - OBSERVED PRECLINICAL SYNERGIES BETWEEN DAROVASERTIB AND CRIZOTINIB IN RELEVANT CELLULAR MODELS

  • IDEAYA BIOSCIENCES INC - OBSERVED EARLY CLINICAL EFFICACY OF DAROVASERTIB AND CRIZOTINIB COMBINATION IN MUM

Source text for Eikon: ID:nPn3VNCvRa

Further company coverage: IDYA.O


(([email protected];))